On 12 December 2025, Celltrion announced that it has successfully secured reimbursement coverage for Avtozma® IV, biosimilar to Roche’s Actemra® (tocilizumab), in the US, having signed a listing agreement with Synergie Collective, one of the top five prescription drug benefit managers (PBMs) in the United States.
Patient reimbursement for Avtozma® IV will be available from January 2026, and has been designated as a preferred drug for priority prescriptions in all public and private insurance formularies managed by Synergy.
Avtozma® was the third tocilizumab biosimilar approved in the US (January 2025), and was subsequently launched in an IV formulation in October 2025. Biogen/Bio-Thera’s Tofidence®/BAT1806 was the first US approved tocilizumab biosimilar (IV formulation, September 2023; launched May 2024), followed by Fresenius Kabi’s Tyenne® (SC formulation, March 2024; IV formulation launched April 2024; SC formulation launched July 2024).
In February 2025, Avtozma® became the third tocilizumab biosimilar approved in the EU, following Fresenius Kabi’s Tyenne®, in both IV and SC forms in November 2023, and Biogen’s IV Tofidence® in June 2024.
Avtozma® has been granted marketing authorisation in a number of other regions, including as the first tocilizumab biosimilar approved in Australia (May 2025), Japan (September 2022) and New Zealand (December 2025), and was considered for listing on Australia’s PBS at PBAC’s November 2025 meeting (outcomes from that meeting are yet to be published).